Black Diamond Therapeutics, Inc.BDTXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-18.6%
5Y CAGR-6.4%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-18.6%/yr
vs +79.7%/yr prior
5Y CAGR
-6.4%/yr
Recent deceleration
Acceleration
-98.3pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
4 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$49.98M-36.6%
2024$78.78M-8.4%
2023$86.02M-7.3%
2022$92.83M-26.8%
2021$126.87M+82.4%
2020$69.57M+137.2%
2019$29.33M+229.4%
2018$8.90M+116.2%
2017$4.12M-